Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00098124
Status:
COMPLETED
Last Update Posted:
2007-12-24
First Post:
2004-12-03
Brief Title:
Study of Milnacipran for the Treatment of Fibromyalgia
Sponsor:
Forest Laboratories
Organization:
Forest Laboratories
Study Overview
Official Title:
A Phase III Pivotal Multicenter Double-Blind Randomized Placebo-Controlled Study of Milnacipran for the Treatment of Fibromyalgia
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None